XellSmart, a China-based developer of stem cell-based treatments, raised a ~CNY200m (~USD28m) Series A1 led by Qiming Venture Partners, Lilly Asia Ventures, FIG and CSSD, with follow-on from FreesFund, Sequoia China and Next Capital. Read more here and here